Meanwhile, the BSE Sensex was up 123.63 points, or 0.62%, to 20,012.58.
On BSE, 4.05 lakh shares were traded in the counter as against an average daily volume of 53,698 shares in the past one quarter.
The stock hit a high of Rs 738.80 so far during the day, which is also a record high for the counter. The stock hit a low of Rs 720.40 so far during the day. The stock had hit a 52-week low of Rs 507 on 15 June 2012.
The stock had outperformed the market over the past one month till 7 May 2013, rising 15.35% compared with the Sensex's 7.80% rise. The scrip had also outperformed the market in past one quarter, rising 20.15% as against Sensex's 1.58% rise.
The large-cap pharmaceutical company has an equity capital of Rs 89.53 crore. Face value per share is Rs 2.
On a consolidated basis, Lupin's net profit surged 162.2% to Rs 408.10 crore on 34.7% rise in net sales to Rs 2537.40 crore in Q4 March 2013 over Q4 March 2012.
Earnings before interest, tax, depreciation and amortization (EBITDA) spurted 74.5% to Rs 664.90 crore in Q4 March 2013 over Q4 March 2012.
Consolidated net profit rose 51.5% to Rs 1314.20 crore on 35.9% rise in net sales to Rs 9461.60 crore in the year ended March 2013 (FY13) over the year ended March 2012 (FY12). EBITDA grew by 57.5% to Rs 2297.90 crore in FY13 over FY12.
Commenting on the results, Dr. Kamal K. Sharma, Managing Director, Lupin Limited, said, "We have had a great quarter and a remarkable year fuelled by strong business performance in the US and India as well as improved operational efficiencies. We continue on our high growth journey."
Lupin's material cost decreased by 4.9% to 35.6% of net sales, at Rs 903.90 crore during Q4 March 2013 as compared to Rs 763.20 crore during Q4 March 2012.
Manufacturing and other expenses decreased by 0.1% to 27.3% of net sales at Rs 692.30 crore during Q4 March 2013 as compared to Rs 517.60 crore during Q4 March 2012.
Personnel cost decreased by 1.4% to 13.0% of net sales, at Rs 330.90 crore during Q4 March 2013, as against Rs 270.20 crore in Q4 March 2012.
Revenue expenditure on R&D stood at 7.9% of net sales at Rs 199.90 during Q4 March 2013, as compared to Rs 136.40 crore during Q4 March 2012.
During the quarter, the company charged off the residual value of Rs 73.60 crore on account of its intellectual property for the Antara brand, consequent to launch of generics.
Lupin said US and Europe formulation sales (including IP) grew by 47% to Rs 4005.10 crore during the year ended March 2013, as against Rs 2727.80 crore in the year ended March 2012, contributing 42% to overall sales. US brands business contributed 21% of total US sales whereas the generics business contributed 79% during the year ended March 2013.
The India formulations business contributed 22% of the company's overall revenues for the quarter. The segment grew by 43% recording net revenues of Rs 565.90 crore during Q4 March 2013, as compared to Rs 396.60 crore in Q4 March 2012. The Indian market contributed 25% of the company's overall revenues for the year ended March 2013. The India formulations business grew by 24% recording revenues of Rs 2364.40 crore for the year ended March 2013 as compared to Rs 1905.80 crore for the year ended March 2012.
Lupin said its Japan sales (Kyowa + I'rom) grew by 2% clocking net sales of Rs 275.20 crore during Q4 March 2013, as compared to Rs 269.40 crore in Q4 March 2012. Lupin's Japanese business grew by 52% clocking net sales of Rs 1304 crore during the year ended March 2013 as compared to Rs 860.70 crore during the year ended March 2012 and contributed 14% to the company's consolidated revenues.
Lupin's South African subsidiary, Pharma Dynamics clocked in revenues of Rs 90.60 crore during Q4 March 2013, representing a growth of 29%. Pharma Dynamics clocked in revenues of Rs 321 crore in the year ended March 2013 as compared to Rs 255.40 crore during the year ended March 2012, representing a growth of 26%.
Lupin said active pharmaceutical ingredient (API) sales grew by 12% to Rs 949.80 crore during the year ended March 2013, contributing to 10% to Lupin's consolidated revenues.
Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations and active pharmaceutical ingredients. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and Cephalosporin segment.
Powered by Capital Market - Live News
